CRISPR 治療公司

SecurityCRSP / CRISPR Therapeutics AG
InstitutionUBS Group AG
Latest Disclosed Ownership1,762,530 shares
Latest Disclosed Value $ 83,843,552
UBS Group AG ownership in CRSP / CRISPR Therapeutics AG

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 1,762,530 shares of CRISPR Therapeutics AG (US:CRSP) valued at $83,843,552 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 2,524,144 shares of CRISPR Therapeutics AG. This represents a change in shares of -30.17% during the quarter. The current value of the position is $100,376,084 USD.

UBS Group AG has a history of taking positions in derivatives of the underlying security (CRSP) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

CRSP / CRISPR Therapeutics AG Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,762,530 -761,614 -30.17 83,844 -36.66 0.0023
2026-01-29 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,524,144 185,088 7.91 132,366 -12.68 0.0215
2025-11-13 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,339,056 -504,521 -17.74 151,594 9.60 0.0237
2025-08-14 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,843,577 771,685 37.25 138,312 96.17 0.0239
2025-05-13 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,071,892 87,902 4.43 70,506 -9.71 0.0130
2025-02-14 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,983,990 1,310,402 194.54 78,090 146.77 0.0144
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 673,588 249,372 58.78 31,645 38.12 0.0069
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 424,216 103,839 32.41 22,912 4.92 0.0057
2024-05-13 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 320,377 9,472 3.05 21,837 12.20 0.0054
2024-02-09 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 310,905 -26,225 -7.78 19,463 27.19 0.0058
2023-11-09 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 337,130 74,470 28.35 15,302 3.78 0.0053
2023-08-11 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 262,660 17,807 7.27 14,746 33.15 0.0050
2023-05-12 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 244,853 -203,682 -45.41 11,075 -39.26 0.0040
2023-02-08 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 448,535 180,573 67.39 18,233 4.11 0.0068
2022-11-10 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 267,962 34,043 14.55 17,512 23.19 0.0077
2022-08-10 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 233,919 30,487 14.99 14,216 11.33 0.0058
2022-05-16 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 203,432 13,542 7.13 12,769 -11.26 0.0043
2022-02-14 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 189,890 50,237 35.97 14,390 -7.94 0.0041
2021-11-15 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 139,653 23,879 20.63 15,631 -16.60 0.0049
2021-08-13 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 115,774 -122,105 -51.33 18,742 -35.34 0.0060
2021-05-12 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 237,879 102,618 75.87 28,985 39.96 0.0096
2021-02-11 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 135,261 42,068 45.14 20,710 165.68 0.0070
2020-11-12 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 93,193 8,799 10.43 7,795 25.69 0.0029
2020-07-31 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 84,394 15,848 23.12 6,202 113.35 0.0026
2020-05-01 2020-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 68,546 12,153 21.55 2,907 -15.37 0.0014
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 56,393 10,936 24.06 3,435 84.38 0.0012
2019-11-14 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 45,457 -11,507 -20.20 1,863 -30.56 0.0007
2019-08-14 2019-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 56,964 570 1.01 2,683 33.15 0.0010
2019-05-14 2019-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 56,394 5,400 10.59 2,015 38.30 0.0008
2019-02-14 2018-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 50,994 -30,560 -37.47 1,457 -59.72 0.0007
2018-11-14 2018-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 81,554 -971 -1.18 3,617 -25.41 0.0014
2018-08-14 2018-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 82,525 23,130 38.94 4,849 78.60 0.0021
2018-05-15 2018-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 59,395 57,025 2,406.12 2,715 4,748.21 0.0012
2018-02-14 2017-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,370 1,800 315.79 56 460.00 0.0000
2017-11-14 2017-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 570 -958 -62.70 10 -60.00 0.0000
2017-11-14 2017-06-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 1,528 958 168.07 25 108.33 0.0000
2017-08-14 2017-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,528 958 25
2017-11-14 2017-03-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 570 -3,472 -85.90 12 -85.37 0.0000
2017-05-12 2017-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 570 -3,472 12
2017-02-14 2016-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 4,042 4,042 82 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-01-29 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-11-13 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 44,508 248.15 2,885 364.41 n/a n/a n/a
2025-08-14 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 12,784 0.00 622 42.76 n/a n/a n/a
2025-05-13 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 12,784 0.00 435 -13.52 n/a n/a n/a
2025-02-14 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 12,784 -37.07 503 -47.27 n/a n/a n/a
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 20,314 -44.95 954 -52.11 n/a n/a n/a
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 36,899 -5.59 1,993 -25.20 n/a n/a n/a
2024-05-13 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 39,084 -47.20 2,664 -42.52 n/a n/a n/a
2024-02-09 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 74,020 293.72 4,634 443.14 n/a n/a n/a
2023-11-09 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 18,800 0.00 853 -19.15 n/a n/a n/a
2023-08-11 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 18,800 0.00 1,055 24.12 n/a n/a n/a
2023-05-12 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 18,800 850 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-01-29 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-11-13 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 40,000 2,592 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.